COMP <GO>
ARDX vs HELP // EV/EBITDA & P/E VALUATION
Ardelyx Inc. (NASDAQ) VS. Helus Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ARDX 0
— HELP 2
■ METRIC PARITY
LAST: $3.10 (0.00%) • MKT CAP: $772.5M
valuation
—
LAST: $10.71 (-1.83%) • MKT CAP: $782.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. HELP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARDX | HELP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.69% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -10.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -15.20% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 22.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.3 | 44.7 | -7.41 | HELP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $772.5M | $782.5M | -$10.0M | HELP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARDX REV | HELP REV | ARDX GROSS % | HELP GROSS % | ARDX FCF | HELP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $407.3M | — | 90.3% | — | -$44.0M | — |
| FY 2024 | $333.6M | — | 84.8% | — | -$45.8M | — |
| FY 2023 | $124.5M | — | — | — | -$89.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
HELP // BETA —